Borja J. Hernández-García

Dr. Borja J. Hernández-García

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
ELEnrique Luengo
Enrique Luengo
IBIzaskun Buendia
Izaskun Buendia
CFCristina Fernández‐Mendívil
Cristina Fernández‐Mendívil
PTPaula Trigo‐Alonso
Paula Trigo‐Alonso
PNPilar Negredo
Pilar Negredo
Manuela G. LopezManuela G. Lopez
Manuela G. Lopez

9 May 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
EPEsther Parada
Esther Parada
ACAna I. Casas
Ana I. Casas
APAlejandra Palomino‐Antolin
Alejandra Palomino‐Antolin
VGVanessa Gómez‐Rangel
Vanessa Gómez‐Rangel
ARAlfonso Rubio-Navarro
Alfonso Rubio-Navarro
Javier EgeaJavier Egea
Javier Egea
Background and Purpose: Ischaemic stroke is a leading cause of death, disability, and a high unmet medical need. Post‐reperfusion inflammation and an up‐regulation of toll‐like receptor 4 (TLR4), an upstream sensor of innate immunity, are associated with poor outcome in stroke patients. Here, we identified the therapeutic effect of targeting the LPS/TLR4 signal transduction pathway.Experimental Approach: We tested the effect of the TLR4 inhibitor, eritoran (E5564) in different in vitro ischaemia‐related models: human organotypic cortex culture, rat organotypic hippocampal cultures, and primary mixed glia cultures. We explored the therapeutic window of E5564 in the transient middle cerebral artery occlusion model of cerebral ischaemia in mice.Key Results: In vivo, administration of E5564 1 and 4 hr post‐ischaemia reduced the expression of different pro‐inflammatory chemokines and cytokines, infarct volume, blood–brain barrier breakdown, and improved neuromotor function, an important clinically relevant outcome. In the human organotypic cortex culture, E5564 reduced the activation of microglia and ROS production evoked by LPS.Conclusion and Implications: TLR4 signalling has a causal role in the inflammation associated with a poor post‐stroke outcome. Importantly, its inhibition by eritoran (E5564) provides neuroprotection both in vitro and in vivo, including in human tissue, suggesting a promising new therapeutic approach for ischaemic stroke.

1 June 2019 in Neurología
Verified
Journal Article
Open access
JGJ. Giner
J. Giner
CLC. Pérez López
C. Pérez López
BHBorja J. Hernández-García
Borja J. Hernández-García
ÁRÁ. Gómez de la Riva
Á. Gómez de la Riva
AIA. Isla
A. Isla
JRJ.M. Roda
J.M. Roda
Much has been published on syringomyelia related to Chiari malformation. In contrast, little is known about the condition when it is not associated with this malformation, but this presentation of syringomyelia constitutes a different entity and therefore requires specific management. We conducted a literature review to summarise the most accepted and widespread ideas about the pathophysiology, management and other aspects of syringomyelia unrelated to Chiari malformation. We reviewed the most relevant literature on this condition, focusing on the pathophysiology, clinical presentation, diagnosis, and treatment. Syringomyelia unrelated to Chiari malformation is a distinct entity that must be well understood to guarantee correct diagnosis, monitoring, and management. When the disease is suspected, a thorough study should be conducted to identify its aetiology. Treatment must aim to eliminate the cause of the disease; symptomatic treatment should remain a second-line option.

1 October 2011 in Neuroscience Letters
Verified
Journal Article
Closed access
JSJavier Saceda
Javier Saceda
AIAlberto Isla
Alberto Isla
SSSusana Santiago
Susana Santiago
CMCarmen Morales
Carmen Morales
COCristina Odene
Cristina Odene
KDKenan Deniz
Kenan Deniz

25 May 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
VFVictor Farré
Victor Farré
APAlejandra Palomino
Alejandra Palomino
PNPaloma Narros
Paloma Narros
ARAna Belen Lopez Rodriguez
Ana Belen Lopez Rodriguez
CDCéline Decouty
Céline Decouty
Javier EgeaJavier Egea
Javier Egea
Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical and pathophysiological processes triggered after the trauma is essential. Here, we identified the serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between inflammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC) of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1 levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.

1 May 2018 in Neurocirugia
Verified
Journal Article
Closed access
AGAlberto Isla Guerrero
Alberto Isla Guerrero
BFBeatriz Mansilla Fernández
Beatriz Mansilla Fernández
BHBorja J. Hernández-García
Borja J. Hernández-García
ÁRÁlvaro Gómez de la Riva
Álvaro Gómez de la Riva
MGMaría Luisa Gandía González
María Luisa Gandía González
EPElena Isla Paredes
Elena Isla Paredes